Corrigendum: Enhanced cytotoxic effects of combined valproic acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer cells [Front Oncol., 3, (2013), 58.] Doi: 10.3389/fonc.2013.00058

Yanfang Li, Tao Liu, Cristina Ivan, Jie Huang, De Yu Shen, John J. Kavanagh, Robert C. Bast, Siqing Fu, Wei Hu, Anil K. Sood

Research output: Contribution to journalComment/debatepeer-review

1 Scopus citations

Abstract

In the original article, while there was no error in the legend for Figures 5A,B as published, we would like to clarify the apparent duplication of the control in the Figures 5A,B, which was because the experiments presented in the Figures 5A,B were carried out at the same time and the control presented in both panels was the same. The edited legend appears below. The authors would like to state that this does not change the scientific conclusions of the article in any way. Additional supplementary figures are also provided below to corroborate our originally published scientific conclusions.

Original languageEnglish (US)
Article number9
JournalFrontiers in Oncology
Volume8
Issue numberFEB
DOIs
StatePublished - Feb 9 2018

Keywords

  • Aurora kinase inhibitor
  • Cervical cancer
  • Endometrial cancer
  • Ovarian cancer
  • Valproic acid

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Corrigendum: Enhanced cytotoxic effects of combined valproic acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer cells [Front Oncol., 3, (2013), 58.] Doi: 10.3389/fonc.2013.00058'. Together they form a unique fingerprint.

Cite this